SANA NASDAQ
Sana Biotechnology, Inc.
1W: -2.0%
1M: -25.7%
3M: -27.2%
YTD: -31.0%
1Y: -21.9%
3Y: -27.2%
5Y: -86.7%
$2.89
+0.00 (+0.00%)
Weekly Expected Move ±9.9%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-10-19
Earliest Filing
2022-01-11
Latest Filing
licensee: 3
partner: 1
Counterparties (Filed by SANA)
4 relationshipsCompanies named in SANA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| National Institutes of Health | — | licensee | Granted exclusive worldwide commercial license for CD22 CAR construct patents | 2022-01-11 | View |
| National Cancer Institute | — | licensee | Represented the NIH in the Patent License Agreement | 2022-01-11 | View |
| U.S. Department of Health and Human Services | — | licensee | Government entity represented by the NIH in the Patent License Agreement | 2022-01-11 | View |
| Beam Therapeutics Inc. | BEAM | partner | Sana Biotechnology entered into an Option and License Agreement to obtain non-exclusive rights to Beam's CRISPR Cas12b n | 2021-10-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-05-15 | Other Events | View | |
| 2026-04-24 | Officer/Director Change | View | |
| 2026-04-13 | Other Events; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-17 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-05 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-08-29 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-08-06 | Results of Operations and Financial Condition; Other Events | View | |
| 2025-06-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR